JP2002506445A - スーパーオキシドラジカルの不均化反応のための合成触媒を用いる鎮痛方法 - Google Patents
スーパーオキシドラジカルの不均化反応のための合成触媒を用いる鎮痛方法Info
- Publication number
- JP2002506445A JP2002506445A JP50459399A JP50459399A JP2002506445A JP 2002506445 A JP2002506445 A JP 2002506445A JP 50459399 A JP50459399 A JP 50459399A JP 50459399 A JP50459399 A JP 50459399A JP 2002506445 A JP2002506445 A JP 2002506445A
- Authority
- JP
- Japan
- Prior art keywords
- independently
- attached
- catalyst
- nitrogen
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003054 catalyst Substances 0.000 title claims abstract description 49
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 title claims abstract description 12
- 238000007323 disproportionation reaction Methods 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title claims description 27
- 230000000202 analgesic effect Effects 0.000 title claims description 21
- 239000000014 opioid analgesic Substances 0.000 claims abstract description 9
- 230000002441 reversible effect Effects 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 44
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 43
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 42
- 125000004432 carbon atom Chemical group C* 0.000 claims description 32
- 208000002193 Pain Diseases 0.000 claims description 31
- 230000036407 pain Effects 0.000 claims description 31
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 22
- -1 transition metal coordination complex Chemical class 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 229920006395 saturated elastomer Polymers 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229960005181 morphine Drugs 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 230000036592 analgesia Effects 0.000 claims description 7
- 239000010949 copper Substances 0.000 claims description 6
- 150000002678 macrocyclic compounds Chemical class 0.000 claims description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 229910052723 transition metal Inorganic materials 0.000 claims description 6
- 239000011701 zinc Substances 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- 229930194542 Keto Natural products 0.000 claims description 4
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 4
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000000477 aza group Chemical group 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 229910000085 borane Inorganic materials 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 claims description 4
- VURFVHCLMJOLKN-UHFFFAOYSA-N diphosphane Chemical compound PP VURFVHCLMJOLKN-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000000468 ketone group Chemical group 0.000 claims description 4
- 229910052748 manganese Inorganic materials 0.000 claims description 4
- 239000011572 manganese Substances 0.000 claims description 4
- 239000013110 organic ligand Substances 0.000 claims description 4
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 claims description 4
- 125000005499 phosphonyl group Chemical group 0.000 claims description 4
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims description 4
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 150000003624 transition metals Chemical class 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 230000007246 mechanism Effects 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims description 2
- 230000002650 habitual effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000003637 steroidlike Effects 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims 1
- 241000406668 Loxodonta cyclotis Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229940125797 compound 12 Drugs 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 abstract description 17
- 208000000114 Pain Threshold Diseases 0.000 abstract description 13
- 230000037040 pain threshold Effects 0.000 abstract description 13
- 229940035676 analgesics Drugs 0.000 abstract description 6
- 239000000730 antalgic agent Substances 0.000 abstract description 6
- 206010003246 arthritis Diseases 0.000 abstract description 3
- 230000000917 hyperalgesic effect Effects 0.000 abstract description 2
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 15
- 239000000679 carrageenan Substances 0.000 description 14
- 235000010418 carrageenan Nutrition 0.000 description 14
- 229920001525 carrageenan Polymers 0.000 description 14
- 229940113118 carrageenan Drugs 0.000 description 14
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 14
- 208000004454 Hyperalgesia Diseases 0.000 description 12
- 208000035154 Hyperesthesia Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 6
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 206010048010 Withdrawal syndrome Diseases 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000002840 nitric oxide donor Substances 0.000 description 4
- 239000006186 oral dosage form Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000007910 systemic administration Methods 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 229960002986 dinoprostone Drugs 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 3
- 229960004752 ketorolac Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 229910001428 transition metal ion Inorganic materials 0.000 description 2
- 108020001588 κ-opioid receptors Proteins 0.000 description 2
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 102000010906 Cyclooxygenase 1 Human genes 0.000 description 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 description 1
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000003752 hydrotrope Substances 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 230000035859 hyperreflexia Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M nitrite group Chemical group N(=O)[O-] IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 208000016153 withdrawal disease Diseases 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5040297P | 1997-06-20 | 1997-06-20 | |
| US60/050,402 | 1997-06-20 | ||
| PCT/US1998/012231 WO1998058636A1 (en) | 1997-06-20 | 1998-06-15 | Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002506445A true JP2002506445A (ja) | 2002-02-26 |
| JP2002506445A5 JP2002506445A5 (enExample) | 2007-12-06 |
Family
ID=21965044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50459399A Ceased JP2002506445A (ja) | 1997-06-20 | 1998-06-15 | スーパーオキシドラジカルの不均化反応のための合成触媒を用いる鎮痛方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6180620B1 (enExample) |
| EP (1) | EP1001752B1 (enExample) |
| JP (1) | JP2002506445A (enExample) |
| AT (1) | ATE256467T1 (enExample) |
| AU (1) | AU733415B2 (enExample) |
| CA (1) | CA2294155A1 (enExample) |
| DE (1) | DE69820633T2 (enExample) |
| DK (1) | DK1001752T3 (enExample) |
| ES (1) | ES2215305T3 (enExample) |
| PT (1) | PT1001752E (enExample) |
| WO (1) | WO1998058636A1 (enExample) |
| ZA (1) | ZA985376B (enExample) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007513948A (ja) * | 2003-12-11 | 2007-05-31 | アルコン，インコーポレイテッド | 視神経損傷および網膜損傷の処置のためのスーパーオキシドジスムターゼ模倣物 |
| JP2014526562A (ja) * | 2011-09-26 | 2014-10-06 | ガレラ・セラピューティクス・リミテッド・ライアビリティ・カンパニー | 疾患の治療方法 |
| JP2018525388A (ja) * | 2015-08-11 | 2018-09-06 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ | 経口バイオアベイラビリティを有するペンタアザ大環状環錯体 |
| US10610533B2 (en) | 2006-10-12 | 2020-04-07 | Galera Labs, Llc | Methods of treating oral mucositis |
| US11246950B2 (en) | 2017-04-13 | 2022-02-15 | Galera Labs, Llc | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
| US12156863B2 (en) | 2016-09-01 | 2024-12-03 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound |
| US12220420B2 (en) | 2016-05-03 | 2025-02-11 | Galera Labs, Llc | Combination therapy for cancer treatment |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6127356A (en) | 1993-10-15 | 2000-10-03 | Duke University | Oxidant scavengers |
| US20060270639A1 (en) * | 1997-06-20 | 2006-11-30 | Daniela Salvemini | Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs |
| US20050171198A1 (en) * | 1997-06-20 | 2005-08-04 | Metaphore Pharmaceuticals, Inc. | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease |
| US6214817B1 (en) * | 1997-06-20 | 2001-04-10 | Monsanto Company | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| CA2309154C (en) | 1997-11-03 | 2010-02-16 | Duke University | Substituted porphyrins |
| ATE552260T1 (de) * | 1999-01-25 | 2012-04-15 | Nat Jewish Health | Substituierte porphyrine und deren therapeutische verwendung |
| AU5048400A (en) | 1999-05-27 | 2000-12-18 | Monsanto Company | Biomaterials modified with superoxide dismutase mimics |
| US20030069281A1 (en) * | 2000-06-14 | 2003-04-10 | Irwin Fridovich | Tetrapyrroles |
| US20020072512A1 (en) * | 2000-12-08 | 2002-06-13 | Metaphore Pharmaceuticals, Inc | Method of preventing and treating HIV-mediated central nervous system damage |
| US20050175580A1 (en) * | 2001-01-05 | 2005-08-11 | Daniela Salvemini | Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines |
| ATE439134T1 (de) * | 2001-01-19 | 2009-08-15 | Nat Jewish Med & Res Center | Medikament zum schutz in der radiotherapie |
| WO2002058686A2 (en) * | 2001-01-26 | 2002-08-01 | Metaphore Pharmaceuticals, Inc. | Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes |
| EP1405066B1 (en) * | 2001-03-02 | 2015-06-17 | Galera Therapeutics LLC | Chromatography of metal complexes |
| US20040137638A1 (en) * | 2002-03-04 | 2004-07-15 | Slomczynska Urszula J. | Chromatography of metal complexes |
| AU2002312194B8 (en) * | 2001-06-01 | 2008-05-15 | Aeolus Sciences, Inc. | Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance |
| AU2002315001A1 (en) * | 2001-06-08 | 2002-12-23 | Metaphore Pharmaceuticals, Inc. | Libraries of conformationally constrained peptides, chiral azacrowns, and peptidomimetics and methods of making the same |
| JP2005519852A (ja) * | 2001-06-26 | 2005-07-07 | メタファー・ファーマシューティカルズ・インコーポレイテッド | 炎症性疾患の予防および／または処置のためのＳＯＤｍとコルチコステロイドの組合せ療養 |
| WO2003039561A1 (en) * | 2001-11-02 | 2003-05-15 | Elan Corporation, Plc | Pharmaceutical composition |
| PT1463563E (pt) * | 2001-12-14 | 2009-03-19 | Alcon Inc | Miméticos de dismutase do superóxido para o tratamento de distúrbios e doenças oculares |
| US6933275B2 (en) * | 2002-05-01 | 2005-08-23 | The Board Of Trustees Of The Leland Stanford Junior University | Protein kinase C peptides for use in withdrawal |
| EP1513537A4 (en) * | 2002-06-07 | 2006-09-06 | Univ Duke | Substituted porphyrins |
| US20030232784A1 (en) * | 2002-06-14 | 2003-12-18 | Benedict James J. | Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain |
| CA2397684A1 (en) * | 2002-08-12 | 2004-02-12 | Michael P. Murphy | Mitochondrially targeted antioxidants |
| CA2499994C (en) * | 2002-09-23 | 2012-07-10 | Verion, Inc. | Abuse-resistant pharmaceutical compositions |
| MXPA05005937A (es) * | 2002-12-06 | 2005-08-18 | Alcon Inc | Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares. |
| CN1717234A (zh) * | 2002-12-06 | 2006-01-04 | 爱尔康公司 | 用于治疗眼紊乱和疾病的超氧化物岐化酶模拟物 |
| KR100648618B1 (ko) * | 2003-11-19 | 2006-11-23 | 주식회사 웰스킨 | 활성 산소 억제제 |
| US20120301403A1 (en) | 2007-06-21 | 2012-11-29 | Galera Therapeutics, Llc | Polyethylene glycolated superoxide dismutase mimetics |
| US8217166B2 (en) * | 2005-05-05 | 2012-07-10 | Galera Therapeutics, Llc | Polyethylene glycolated superoxide dismutase mimetics |
| WO2006069326A2 (en) * | 2004-12-21 | 2006-06-29 | Metaphore Pharmaceuticals, Inc. | Polyethylene glycolated superoxide dismutase mimetics |
| KR100724586B1 (ko) | 2005-12-09 | 2007-06-04 | 세종대학교산학협력단 | 수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물 |
| WO2009065059A2 (en) | 2007-11-14 | 2009-05-22 | Kereos, Inc. | Super-oxide dismutase mimetics |
| ES2530462T3 (es) | 2008-05-22 | 2015-03-03 | Galera Therapeutics Llc | Combinación terapia antitumoral |
| EP2732817B1 (en) | 2008-05-23 | 2016-08-24 | National Jewish Health | A compound for use in treating injury associated with exposure to phosgene or chlorine gas |
| CA3053779A1 (en) | 2017-02-15 | 2018-08-23 | Galera Labs, Llc | Pentaaza macrocyclic ring complexes for local intestinal delivery |
| EP3388082A1 (en) | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
| AU2019215032A1 (en) | 2018-01-31 | 2020-09-10 | Board Of Regents Of The University Of Texas System | Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent |
| WO2021163397A1 (en) | 2020-02-13 | 2021-08-19 | Teva Pharmaceuticals International Gmbh | Solid state forms of avasopasem manganese and process for preparation thereof |
| WO2025024390A2 (en) * | 2023-07-21 | 2025-01-30 | Galera Labs, Llc | Carcinogenesis reduction with pentaaza macrocyclic ring complex |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0751496B2 (ja) | 1986-04-02 | 1995-06-05 | 武田薬品工業株式会社 | リポソ−ムの製造法 |
| US4999347A (en) | 1986-08-28 | 1991-03-12 | Sorenson John R J | Analgesic method |
| US5216021A (en) | 1986-08-28 | 1993-06-01 | Sorenson John R J | Analgesic method |
| JPS63313581A (ja) * | 1987-06-16 | 1988-12-21 | Ube Ind Ltd | 修飾ス−パ−オキシドジスムタ−ゼ |
| CA2072934C (en) | 1991-07-19 | 2007-08-28 | Karl William Aston | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| DE69224839T2 (de) | 1991-07-19 | 1998-10-08 | Monsanto Co | Mangan-Komplexe mit Stickstoff enthaltenden makrozyklischen Liganden, wirksam als Superoxiddismutasekatalysatoren. |
| CN1088086A (zh) * | 1992-12-14 | 1994-06-22 | 西北大学 | 一种新型的护肤保健品 |
| US6204259B1 (en) | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| US6525041B1 (en) | 1995-06-06 | 2003-02-25 | Pharmacia Corporation | Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| IL125889A0 (en) | 1996-03-13 | 1999-04-11 | Monsanto Co | Bioconjugates of manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
-
1998
- 1998-04-09 US US09/057,831 patent/US6180620B1/en not_active Expired - Fee Related
- 1998-06-15 AT AT98929022T patent/ATE256467T1/de not_active IP Right Cessation
- 1998-06-15 DE DE69820633T patent/DE69820633T2/de not_active Expired - Fee Related
- 1998-06-15 AU AU80685/98A patent/AU733415B2/en not_active Ceased
- 1998-06-15 WO PCT/US1998/012231 patent/WO1998058636A1/en not_active Ceased
- 1998-06-15 CA CA002294155A patent/CA2294155A1/en not_active Abandoned
- 1998-06-15 DK DK98929022T patent/DK1001752T3/da active
- 1998-06-15 PT PT98929022T patent/PT1001752E/pt unknown
- 1998-06-15 ES ES98929022T patent/ES2215305T3/es not_active Expired - Lifetime
- 1998-06-15 JP JP50459399A patent/JP2002506445A/ja not_active Ceased
- 1998-06-15 EP EP98929022A patent/EP1001752B1/en not_active Expired - Lifetime
- 1998-06-19 ZA ZA985376A patent/ZA985376B/xx unknown
-
2000
- 2000-08-09 US US09/634,152 patent/US6395725B1/en not_active Expired - Fee Related
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007513948A (ja) * | 2003-12-11 | 2007-05-31 | アルコン，インコーポレイテッド | 視神経損傷および網膜損傷の処置のためのスーパーオキシドジスムターゼ模倣物 |
| US10610533B2 (en) | 2006-10-12 | 2020-04-07 | Galera Labs, Llc | Methods of treating oral mucositis |
| US11612608B2 (en) | 2006-10-12 | 2023-03-28 | Galera Labs, Llc | Methods of treating oral mucositis |
| JP2023027289A (ja) * | 2011-09-26 | 2023-03-01 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー | 疾患の治療方法 |
| JP2014526562A (ja) * | 2011-09-26 | 2014-10-06 | ガレラ・セラピューティクス・リミテッド・ライアビリティ・カンパニー | 疾患の治療方法 |
| JP7697688B2 (ja) | 2011-09-26 | 2025-06-24 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー | 疾患の治療方法 |
| US11826373B2 (en) | 2011-09-26 | 2023-11-28 | Galera Labs, Llc | Methods for treatment of diseases |
| JP2020183416A (ja) * | 2011-09-26 | 2020-11-12 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ | 疾患の治療方法 |
| US10493081B2 (en) | 2011-09-26 | 2019-12-03 | Galera Labs, Llc | Methods for treatment of diseases |
| JP2018035162A (ja) * | 2011-09-26 | 2018-03-08 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ | 疾患の治療方法 |
| JP7041959B2 (ja) | 2015-08-11 | 2022-03-25 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー | 経口バイオアベイラビリティを有するペンタアザ大環状環錯体 |
| JP2022023183A (ja) * | 2015-08-11 | 2022-02-07 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー | 経口バイオアベイラビリティを有するペンタアザ大環状環錯体 |
| US11066433B2 (en) | 2015-08-11 | 2021-07-20 | Galera Labs, Llc | Pentaaza macrocyclic ring complexes possessing oral bioavailability |
| JP2018525388A (ja) * | 2015-08-11 | 2018-09-06 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ | 経口バイオアベイラビリティを有するペンタアザ大環状環錯体 |
| US12077549B2 (en) | 2015-08-11 | 2024-09-03 | Galera Labs, Llc | Pentaaza macrocyclic ring complexes possessing oral bioavailability |
| US10597415B2 (en) | 2015-08-11 | 2020-03-24 | Galera Labs, Llc | Pentaaza macrocyclic ring complexes possessing oral bioavailability |
| US12220420B2 (en) | 2016-05-03 | 2025-02-11 | Galera Labs, Llc | Combination therapy for cancer treatment |
| US12156863B2 (en) | 2016-09-01 | 2024-12-03 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound |
| US11246950B2 (en) | 2017-04-13 | 2022-02-15 | Galera Labs, Llc | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
Also Published As
| Publication number | Publication date |
|---|---|
| AU733415B2 (en) | 2001-05-17 |
| ATE256467T1 (de) | 2004-01-15 |
| DK1001752T3 (da) | 2004-04-19 |
| DE69820633D1 (de) | 2004-01-29 |
| DE69820633T2 (de) | 2004-09-23 |
| CA2294155A1 (en) | 1998-12-30 |
| WO1998058636A1 (en) | 1998-12-30 |
| AU8068598A (en) | 1999-01-04 |
| EP1001752A1 (en) | 2000-05-24 |
| EP1001752B1 (en) | 2003-12-17 |
| US6395725B1 (en) | 2002-05-28 |
| ZA985376B (en) | 1999-06-21 |
| ES2215305T3 (es) | 2004-10-01 |
| PT1001752E (pt) | 2004-05-31 |
| US6180620B1 (en) | 2001-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002506445A (ja) | スーパーオキシドラジカルの不均化反応のための合成触媒を用いる鎮痛方法 | |
| JPS6075429A (ja) | 鎮痛用組成物 | |
| JPS6084251A (ja) | 鎮痛用新規化合物および組成物 | |
| JPH0510334B2 (enExample) | ||
| CA2338066C (en) | Treatment of dyskinesia | |
| HUE026994T2 (en) | Liquid nasal spray containing low dose naltrexone | |
| EP0278821A1 (fr) | Utilisation d'antagonistes de la morphine dans la préparation de médicaments à effet immunomodulateur et anti-viral, destinés notamment à traiter les états immuno-déficitaires acquis | |
| AU2021204517B2 (en) | Combination of opioids and n-acylethanolamines | |
| US20040147498A1 (en) | Combinations of superoxide dismutase mimetics and nonsteroidal analgesic / anti-inflammatory drugs | |
| JP5416327B2 (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| CA3053779A1 (en) | Pentaaza macrocyclic ring complexes for local intestinal delivery | |
| JP2000506170A (ja) | 酸化窒素スキャベンジャーを用いる複合治療方法とそのために有用な組成物 | |
| JPH02500368A (ja) | 温血動物における腫瘍阻止方法 | |
| US20050171198A1 (en) | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease | |
| FR2556216A1 (fr) | Nouveau medicament analgesique contenant du proglumide, eventuellement en association avec des medicaments analgesiques-narcotiques | |
| WO2005041886A2 (en) | Methods for generating or increasing revenues related to pain inhibitor commerce | |
| WO2019151409A1 (ja) | 鎮痛剤及び鎮静剤 | |
| JPH0326171B2 (enExample) | ||
| WO2025198489A1 (ru) | Анальгетическая субстанция эндогенной природы, фармацевтическая композиция на ее основе и способы их применения | |
| WO2005060437A2 (en) | Composition combinations and methods for treating, preventing, reversing and inhibiting pain | |
| TW202132291A (zh) | 使用苯氧丙胺化合物治療疼痛的方法 | |
| WO2005041894A2 (en) | Compositions and methods for treating, preventing, reversing and inhibiting pain | |
| PT88309B (pt) | Processo para a preparacao de esteres de butilo terciario de drogas anticancerigenas e sua utilizacao para melhorar a administracao das drogas ao cerebro | |
| WO2019191597A1 (en) | Very long chain saturated fatty acid compounds, compositions containing same, and methods of use | |
| WO2007105286A1 (ja) | 血中脂質低下剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050615 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050615 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070628 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080812 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081112 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081222 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081212 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090126 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090113 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090212 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090512 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20090929 |